Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Boosted by Dodge & Cox

Dodge & Cox increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,321,316 shares of the biopharmaceutical company's stock after acquiring an additional 9,381 shares during the period. Dodge & Cox owned approximately 2.11% of Regeneron Pharmaceuticals worth $1,653,543,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on REGN shares. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Bank of America dropped their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Finally, BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $963.56.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $13.88 on Friday, hitting $563.16. The company's stock had a trading volume of 827,663 shares, compared to its average volume of 711,859. The company has a market capitalization of $61.57 billion, a price-to-earnings ratio of 14.71, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The stock's 50-day moving average is $647.99 and its two-hundred day moving average is $743.86.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.